Clinical Trial Update: A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN [Phase 2]

View source ↗

Summary

Phase 2 trial assessing danicopan effects on C3 levels in participants with C3 glomerulopathy or IC-MPGN; the study is completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulonephritis
• C3 Glomerulopathy
• Dense Deposit Disease
• Immune Complex-mediated Membranoproliferative Glomerulonephritis
• Membranoproliferative Glomerulonephritis Types Ii and Iii

Drugs mentioned

• Danicopan (danicopan)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: C3 Glomerulonephritis, Dense Deposit Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-07-13